Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep750 | Pituitary and Neuroendocrinology | ECE2020

Country-specific differences in adult growth hormone deficiency diagnosis and treatment rates

Nedjatian Navid , den Hollander Bjørnar , Amirouche Yacine

Background: Adult growth hormone deficiency (AGHD) is a rare disease associated with adverse metabolic abnormalities and possibly increased cardiovascular morbidity and mortality. Although basic prevalence data is available, little is known about the rates of diagnosed and treated patients.Aim: To understand the rates of AGHD diagnosis/treatment and details about patients’ growth hormone (GH) dose, age and treatment duration....

ea0073oc13.3 | Oral Communications 13: Pituitary and Neuroendocrinology | ECE2021

Cardiovascular and metabolic safety of growth hormone treatment in adult patients with growth hormone deficiency: real-world data from two large studies in the USA and Europe

Charlotte Höybye , Kelepouris Nicky , Nedjatian Navid

IntroductionEvidence suggests that adults with growth hormone deficiency (AGHD) exhibit metabolic abnormalities that are typical of the metabolic syndrome and are risk factors for type 2 diabetes (T2D). Concerns about undesirable effects of growth hormone replacement therapy (GHRT) on glucose metabolism have been raised, but the risk of T2D from AGHD has mixed evidence. This analysis aims to evaluate cardiovascular (CV) and metabolic safety of GHRT in th...

ea0081ep673 | Pituitary and Neuroendocrinology | ECE2022

Growth hormone (GH) replacement therapy (GHRT) in patients with adult GH deficiency (AGHD) aged ≥60 years: data from NordiNet® IOS and the ANSWER Program

M. Weber Matthias , B. Gordon Murray , Hoybye Charlotte , H. Olsen Anne , Kelepouris Nicky , Nedjatian Navid , M.K. Biller Beverly

Introduction: There are limited data on the effectiveness and safety of GHRT in older patients with AGHD. We compared real-world GHRT outcomes in older (aged ≥60 years) vs middle-aged (35–<60 years) adults.Methods: NordiNet® IOS (NCT00960128) and ANSWER (NCT01009905) were non-interventional studies investigating long-term effectiveness and safety of GHRT with Norditropin® (somatropin, Novo Nordisk). Safety was assessed in the ful...

ea0081p415 | Pituitary and Neuroendocrinology | ECE2022

Effects of somapacitan on glucose metabolism in adults with GH deficiency

Johannsson Gudmundur , MK Biller Beverly , Fukuoka Hidenori , Ho Ken , Hojby Rasmussen Michael , Nedjatian Navid , Svaerke Claus , CJ Yuen Kevin , Takahashi Yutaka

Somapacitan is a once-weekly, long-acting growth hormone (GH) derivative approved for the treatment of adult GH deficiency (AGHD). Our objective was to evaluate the effects of somapacitan on glucose metabolism compared with daily GH or placebo in patients with AGHD using data from three previously published phase 3 trials: REAL 1 (NCT02229851), REAL 2 (NCT02382939) and REAL Japan (NCT03075644). REAL 1 was a randomised, placebo-controlled (double-blind) and active-controlled (o...

ea0070aep1069 | Hot topics (including COVID-19) | ECE2020

The role of growth hormone device optimisation in patient-reported outcomes: Real-world evidence from South Korea

Lee Ji-Eun , Lee Kee-Hyoung , Park Mi Jung , Yang Seung , Young Kim Eun , Rhie Young-Jun , Jung Min-Ho , Yang Aram , Kim Shin-Hye , Yoojin Chung Lindsey , Young Ko Su , Ju Lee Young , Nedjatian Navid , Yeong Chung Woo

Growth hormone (GH) therapy (GHT) requires long-term commitment to daily sc GH injections that may present adherence challenges. Patient preference and adherence have been shown to be affected by delivery devices in association with convenience of administration, level of injection-site pain, confidence in correct dose administration and satisfaction with the device. This survey investigated if switching GH device – from NordiLet/others to NordiFlex – improved pati...